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Abstract Pluripotent stem cells hold great promises for
regenerative medicine. They might become useful as a
universal source for a battery of new cell replacement
therapies. Among the major concerns for the clinical
application of stem cell-derived grafts are the risks of
immune rejection and tumor formation. Pluripotency and
tumorigenicity are closely linked features of pluripotent
stem cells. However, the capacity to form teratomas or
other tumors is not sufficiently described by inherited
features of a stem cell line or a stem cell-derived graft. The
tumorigenicity always depends on the inability of the
recipient to reject the tumorigenic cells. This review
summarizes recent data on the tumorigenicity of pluripotent
stem cells in immunodeficient, syngeneic, allogeneic, and
xenogeneic hosts. The effects of immunosuppressive
treatment and cell differentiation are discussed. Different
immune effector mechanisms appear to be involved in the
rejection of undifferentiated and differentiated cell popula-
tions. Elements of the innate immune system, such as
natural killer cells and the complement system, which are
active also in syngeneic recipients, appear to preferentially
reject undifferentiated cells. This effect could reduce the
risk of tumor formation in immunocompetent recipients.
Cell differentiation apparently increases susceptibility to
rejection by the adaptive immune system in allogeneic
hosts. The current data suggest that the immune system of
the recipient has a major impact on the outcome of
pluripotent stem cell transplantation, whether it is rejection,
engraftment, or tumor development. This has to be
considered when the results of experimental transplantation
models are interpreted and even more when translation into
clinics is planned.
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The relation of pluripotency and tumorigenicity in stem
cells—a challenge for regenerative medicine
Pluripotent stem cells can in principle differentiate into all
cell types of the human body. Therefore, they have the
potential for being used as source of transplantable cells for
many different tissues and may offer new possibilities to
treat various human diseases [1]. However, the use of
human embryonic stem cells (ESCs) is restricted due to
severe ethical concerns. Fortunately, new pluripotent cell
types derived from adult organisms have been described.
The most spectacular breakthrough in this field was
obtained by reprogramming of mouse and human somatic
cells into induced pluripotent stem cells (iPSCs) using a
defined set of transcription factors [2–5]. Notably,
pluripotent cells can also be obtained without the need of
genetic manipulation from the testis of neonatal [6] and
adult mice [7]. The so-called multipotent adult germ-line
stemcells(maGSCs)canbedifferentiatedinvitrointovarious
cell types, including cardiomyocytes [8] and neuronal cells
[9, 10], and they form teratomas in vivo [7, 11]. The
generation of pluripotent cells from adult human testis has
also been recently reported [12–14], but the properties of
these human germ-line stem cells are currently debated [15].
This article is published as part of the special issue on
Immunopathology of Pluripotent Stem Cell Transplantation [33:6].
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demonstrates their potential to differentiate in all tissue
types, is their ability to form teratomas in suitable hosts.
This already indicates the close relationship of pluripotency
and tumorigenicity in pluripotent stem cells. Therefore, it is
not surprising that the risk of tumor formation is among the
major hurdles that must be overcome before implementa-
tion of pluripotent stem cells into clinical practice [16–20].
Teratoma formation in immunodeficient mice is a key assay
to determine the pluripotency of stem cells [21, 22].
Teratomas are tumors that contain tissues of ectodermal,
mesodermal, and endodermal origin and the teratoma assay
is therefore a relatively easy tool to demonstrate the ability
of stem cells to differentiate in tissues derived from all three
embryonic germ layers. For human stem cells, this assay is
currently the ultimate test of pluripotency [23]. The
blastocyst chimerism or tetraploid embryo complementa-
tion followed by gestation, which is used in mouse stem
cell research as even better proof of pluripotency [24, 25],
is prohibited in humans for ethical reasons. Fully differen-
tiated or mature teratomas are composed only of non-
proliferating somatic tissue. Immature teratomas contain
additionally proliferating fetal-like cells. Teratomas grow-
ing after injection of pluripotent stem cells into animal
models are usually non-malignant immature or mature
teratomas [16, 21, 26]. However, in some cases, invasive
or even metastatic tumors were observed after transplanta-
tion of pluripotent stem cells or their derivatives so that
malignant teratocarcinoma-like tumors might occasionally
occur [27]. Teratocarcinomas are defined to contain, in
addition to differentiated tissues and normal immature
precursor cells, also malignant cells that are equivalent to
embryonal carcinoma (EC) cells in humans [28]. Genetic
alteration during cell culture might be one reason for a more
malignant phenotype of some pluripotent stem cell lines.
The generation of iPSCs from adult cells that have acquired
somatic mutations before being reprogrammed and gain
additional genetic and epigenetic alterations during the
reprogramming process aggravates this problem [29–31].
However, mutations giving rise to a more malignant
phenotype of pluripotent stem cells will not be discussed
in this review.
Interestingly, mouse ESCs appear to have a higher risk
to form teratocarcinomas in mice compared to human ESCs
[16]. The reasons could include species-specific growth
factors, which lack in xenogeneic hosts, but also a more
efficient immune-mediated rejection of xenogeneic malig-
nant cells. In this case, human ESCs or other pluripotent
stem cell types could have a higher risk to form
teratocarcinomas in human recipients than predicted by
mouse experiments [16]. Since pluripotency and tumorige-
nicity of pluripotent stem cells are so closely related, it is
not clear whether these phenomena can be uncoupled in
any stem cell line [32]. Pluripotent cells are therefore
unlikely to be used directly in regenerative medicine. More
likely, pluripotent stem cell-derived progenitor cells or
differentiated cells will be transplanted in future cell or
tissue replacement therapies [32]. However, it is presently
not clear, which degree of developmental plasticity is
required for cellular grafts. Terminally differentiated cells
are presumably safe with respect to tumorigenicity but they
might have a limited therapeutic efficacy at least for
potential indications that require integration into host
tissues.
Despite efforts to remove tumorigenic cells from grafts
by various means including prolonged differentiation [33],
cell sorting or selection [34–37], introduction of suicide
genes [38, 39], and killing of undifferentiated cells prior to
transplantation [40–42], all grafts that are derived from
pluripotent stem cells are in principle at risk of containing
teratoma-forming cells [32]. It is not known how many or
few contaminating pluripotent cells could be acceptable
with respect to the safety of a therapeutic graft. Notably, as
few as two mouse ESCs [43] or 245 human ESCs [44] were
reported to be able to form teratomas in immunodeficient
mice. Importantly, teratomas and teratocarcinomas are not
the only tumors that can form out of stem cell-derived
grafts [19]. Transplantation of grafts containing non-
pluripotent lineage committed stem cells might lead to
growth of tumors that are more restricted in their tissue
composition [36, 45, 46]. However, even benign tumors or
normal but ectopically grown tissues (so-called tissue
overgrowth) arising after stem cell therapy could cause
severe clinical problems and would be unacceptable for
most potential therapeutic applications.
Risks of fetal cell transplantations—a caveat
also for stem cell-based transplantation therapies
Two recent reports indicate that the risk of tumor formation
even after fetal cell transplantation might be more serious
than previously anticipated. A patient with Huntington’s
disease, who was transplanted into the striatum with human
fetal neural tissues [47], developed graft-derived “mass
lesions” indicating the potential for graft overgrowth
following fetal neural cell transplantation [48]. These
tumors were detected at autopsy when the patient died
121 months after the transplantation due to progression of
the disease. The patient might have had clinical benefit
from the transplants at earlier stages of the disease [48], and
it has to be noticed that in other patients undergoing the
same or similar procedures, no tumors were found at
autopsy [49, 50]. In a second more debated case, a child
with ataxia telangiectasia was treated at the age of 9, 10,
and 12 years with intracerebellar and intrathecal injections
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13 years donor-derived brain tumors [51]. The trans-
plantations were performed in a setting outside the
scientific mainstream [52], and the clinical complications
were treated and reported by a team not involved in the
transplantation. Parts of the lesions were removed and
identified to be glioneural tumors [51]. In both cases, the
donor-origin of the tumors was proven by genetic means
[48, 51]. However, it is not clear whether the tumors indeed
developed from neural stem cells that might have been
present in the fetal cellular grafts. Therefore, the conclu-
sions which can be drawn from these cases with respect to
cellular transplantation therapies based on better defined
stem cell populations or their purified derivatives, might be
limited [53]. Nonetheless, both cases demonstrate that the
risk of tumor formation has to be taken seriously even after
fetal cell transplantations.
Notably, the immune system of both patients developing
tumors after transplantation of allogeneic fetal cells was
compromised. The patient with Huntington’sd i s e a s e
received an immunosuppressive therapy with cyclosporine
A (CsA) for 12 months after the surgery to avoid graft
rejection [48]. More intriguingly, ataxia telangiectasia is
associated with an immunodeficiency [51, 54] and the
patient was treated for hypogammaglobulinemia since the
age of 7 years [51]. Realization of the tumorigenic potential
of the fetal grafts in these patients could in part be due to a
failure of the recipient’s immune system to control the
growth of tumorigenic donor cells. Transplantation into an
immune-privileged organ such as the brain, immunosup-
pressive treatment, or an inherited or acquired immunode-
ficiency might increase the risk of tumor formation derived
from stem cell grafts.
Tumorigenicity of stem cells—a failure of the recipient’s
immune system to reject tumor-forming cells
Also, in experimental systems, the teratoma-forming ca-
pacity of a pluripotent stem cell line is not sufficiently
described by inherited features of the stem cell line. The
teratomas are always formed in a host. Close interactions
between donor and host tissues were observed after grafting
of human ESCs in immunodeficient mice. Mouse cells
contributed mainly, but not solely, to the formation of
vessels in the human teratomas [26, 55]. It is not well
known which factors provided by the host support the
formation of teratomas after injection of pluripotent cells.
However, it is conceivable that growth factors, cytokines,
and hormones produced by cells of the host influence or
even promote teratoma formation [56].
In addition, the potential of a pluripotent stem cell line
to form teratomas always depends on the failure of the
recipient to reject the teratoma-forming cells. Therefore,
the teratoma assay, which demonstrates the pluripotency
of a stem cell line, is usually performed in immunode-
ficient animals to avoid rejection of the stem cells by the
recipient’s immune system. The therapeutic potential of
stem cells and stem cell-derived grafts is currently
examined in a large variety of animal models involving
transplantations in syngeneic, allogeneic, or even xeno-
geneic settings with or without pharmacological immu-
nosuppression. Furthermore, various immunodeficient
animal models are used for that purpose. Results on the
risk of tumor formation and on engraftment of stem cell-
derived transplants have always to be interpreted in view
of the model that was used. Lack of teratoma formation
in immunocompetent animal models receiving stem cell
transplants may often reflect the ability of the host to
reject tumorigenic cells rather than the absence of those
cells from the grafts. In this case, transplantation of the
same cells into another less immunocompetent or even
immunocompromised recipient might have a much higher
risk of tumor formation. On the other hand, tumor
formation in an immunodeficient animal model could
indicate a risk of tumor formation that is practically not
present in an immunocompetent recipient. Before clinical
application of new stem cell-based therapies, it will be
necessary to examine the risk of tumor development as
well as the chance of successful engraftment of stem
cells or stem cell-derived grafts in various immunoge-
netic settings to realistically appraise both, risks and
chances.
Immune control of teratoma growth—results
from immunodeficient animal models
It is well known that mouse [57–66] and human ESCs [26,
41, 42, 44, 55, 67–74] give rise to teratomas when injected
into immunodeficient hosts. The types of immunodeficient
models used in these experiments include T, B, and natural
killer (NK) cell-deficient RAG2
−/−cγc
−/− [59], and SCID/
beige mice [26, 61, 68, 71, 73, 75], T and B cell-deficient
SCID [41, 42, 44, 70, 72, 75], RAG1
−/− [65], and NOD/
SCID mice [58, 69, 71, 76, 77], the latter having also an
impairment of some innate immune functions. In addition,
T cell-deficient nude mice [43, 55, 60, 62, 64, 66, 76, 78,
79] and nude rats [39, 66] were used and found to allow for
teratoma growth. These data indicate that the T cell
deficiency in nude mice and rats is in principal sufficient
to allow for the growth of allogeneic and even xenogeneic
teratomas. However, it is still not clear which effects the
types of immunodeficiency in these models have on tumor
frequency, tumor growth kinetics, and the minimal number
of cells that needs to be inoculated.
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tumorigenicity of stem cell lines in several immunodefi-
cient models. Probably, the most comprehensive study was
published by Drukker and colleagues for human ESCs [67].
They investigated teratoma growth after injection of 1×10
6
human ESCs under the kidney capsule of NOD/SCID (T
and B cell-deficient), BALB-nude (T cell-deficient),
C57BL/6-Lyst
bg (NK cell-deficient), and CBA/CaHN
Btk
xid (B cell-deficient) mice. They found that T cells
rather than B or NK cells were important for the rejection
of the human ESCs because teratomas were only observed
in the T cell-deficient models, i.e., NOD/SCID and nude
mice at least within 5 weeks after transplantation [67].
Swijnenburg and colleagues compared teratoma growth
after intramuscular injection of 1×10
6 human ESCs into
NOD/SCID, BALB-nude, CD4
−/−, and CD8a
−/− mice [77].
Teratomas were formed in NOD/SCID and nude mice. The
transplanted cells were rejected both in CD4
−/− and CD8a
−/−
mice but with a faster kinetics in CD8a
−/− recipients
suggesting CD4-postive helper T cells to be more important
for the rejection of xenogeneic ESCs than CD8-positive
cytotoxic T cells (CTLs) [77].
It was confirmed that B cells are not important for mouse
ESC rejection when B cell-deficient JH
−/− mice were used
as recipients and did not develop teratomas [59]. In the
s a m es t u d y ,m o u s eE S C s ,i nc o n t r a s tt oi nv i t r o -
differentiated cardiomyocytes, were shown to be highly
susceptible to lysis mediated by the alternative antibody-
independent complement pathway. In C3
−/− mice lacking
the C3 complement factor, the growth of teratomas from
syngeneic ESCs was accelerated at higher cell numbers
(1×10
6) compared to wild-type hosts and the complement
system prevented tumor formation by smaller cell numbers
(1×10
5) in wild-type mice but not in C3
−/− mice [59].
Effects of NK cells on rejection of ESCs have also been
reported. Teratomas derived from human ESCs grew faster
in T, B, and NK cell-deficient SCID/beige compared to T
and B cell-deficient NOD/SCID mice, suggesting an effect
of mouse NK cells on human teratoma growth kinetics [71].
This was further confirmed by NK cell depletion experi-
ments in NOD/SCID mice using anti-asialo GM-1 anti-
bodies [71]. We have further investigated the role of mouse
NK cells in rejection of mouse pluripotent stem cells by
comparing teratoma growth in SCID and SCID/beige mice.
The teratoma frequency was 93 % in SCID/beige (n=14)
and 100% in SCID mice (n=16) (Table 1) within 100 days
after subcutaneous injection of 1×10
6 mouse MPI-II ESCs
[61]. Notably, the tumor growth was accelerated in NK cell-
deficient SCID/beige compared to SCID mice (Fig. 1). In
further experiments, the growth of an ESC, an iPSC, and a
maGSC line was analyzed [75]. The overall teratoma
frequency was 94 % both in SCID and in SCID/beige mice
(n=18; six for each stem cell line). Activation of NK cells
in SCID mice by the Toll-like receptor 3 agonist poly(I:C)
reduced the tumor frequency to 50% and decelerated
teratoma growth [75]. This effect of poly(I:C) injection
was not observed in SCID/beige mice, suggesting that it
was indeed mediated by the activation of NK cells.
Depletion of NK cells in SCID mice by anti-asialo GM1
antibodies prior to stem cell injection was also able to
abrogate the poly(I:C) effect, further confirming the role of
NK cells in rejection of pluripotent stem cells [75]. Thus,
the elements of the innate immune system such as NK cells
or complement system that are intact in many immunode-
ficient mouse models can contribute to the rejection of
pluripotent stem cells.
The teratoma growth after injection of pluripotent stem
cells in immunodeficient animals has been shown to depend
on further factors, such as injected cell numbers [43, 44, 66,
72] and the site of engraftment [43, 44, 57, 69, 72, 73, 78].
The engraftment sites, including subcutaneous space,
muscle, kidney capsule, testis, liver, spleen, and knee joint
might vary with respect to the presence of teratoma-
supporting factors, such as nutrients or more specifically
growth factors. However, they might also vary in accessi-
bility for components of the immune system that are still
present in the respective immunodeficient model and
contribute to the rejection of the graft. It has been
suggested, e.g., that the immune-privileged or tolerance-
promoting environment within the liver may create more
favorable growth conditions for human ESCs grafted into
the liver of nude mice compared to those injected
subcutaneously [78]. Similarly, teratomas developed more
readily in SCID/beige mice after injection of human ESCs
in the testis compared to the heart [73]. Co-injection of non-
stem cells, such as fibroblasts [43, 66], or embedding of
stem cells in Matrigel [43, 44, 66, 69] can also ameliorate
the efficiency of teratoma formation. It can not be excluded
that these factors modulate the immune response against the
stem cells. Moreover, human ESCs were reported to form
typical mature teratomas when injected into SCID mice but
large tumors with undifferentiated OCT-4 positive cell
masses when injected into human fetal grafts implanted
into SCID mice [70]. Thus, human ESCs might grow more
aggressively in a syngeneic microenvironment due to
species-specific growth factors that are provided by the
human fetal grafts [70]. Alternatively, aggressive tumori-
genic cells might be less controllable by the innate immune
system of the host, e.g., mouse NK cells, in a xenogeneic
human microenvironment. The pluripotent stem cell type
might also affect the teratoma growth characteristics. It has
recently been reported that human iPSC lines form
teratomas more efficiently and faster than human ESC lines
in NOD/SCID IL2Rγ
−/− hosts [74].
In conclusion, the results obtained in immunodeficient
mouse models suggest that T cells are required to suppress
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pluripotent stem cells. Presence of functional NK cells
appears regularly not to be sufficient to prevent teratomas
after injection of high numbers of pluripotent stem cells.
However, mouse NK cells can contribute to the rejection of
smaller numbers of mouse and human stem cells and at
least retard tumor growth, especially if NK cells become
activated. Clearly, more studies are needed to better dissect
the contribution of defined elements of the immune system
to the rejection of pluripotent stem cells.
Immune control of teratoma growth—results
from syngeneic transplantations
The injection of mouse ESCs into syngeneic hosts can lead to
teratomas[36, 43, 60, 61, 80–82]. However, only few studies
compared teratoma growth in immunodeficient and immu-
nocompetent syngeneic hosts [43, 61]. Thus, the available
information on the effects of a syngeneic immune system on
transplanted pluripotent stem cells is very limited.
We compared the teratoma growth characteristics of
MPI-II mouse ESCs in allogeneic immunodeficient and in
immunocompetent syngeneic 129Sv mice after subcutane-
ous injection of 1×10
6 cells (Table 1)[ 61]. Although the
tumor frequency was similar (96% in syngeneic, 93% in
SCID/beige, and 100% in SCID hosts), the tumor growth
characteristics were different. In SCID/beige mice, tumors
grew more rapidly than in syngeneic and SCID hosts
(Fig. 1). The similar growth kinetics in SCID and 129Sv
mice suggests that the adaptive immune system is less
important for the decelerated growth of teratomas in
syngeneic compared to SCID/beige mice. Instead, NK cells
might cause this transient delay of tumor progression.
Interestingly, allogeneic (SCID) and syngeneic (129Sv) NK
cells appear to have similar effects. The teratomas in
syngeneic mice were infiltrated with T and B cells as well
as macrophages, but these cells were obviously not able to
reject the teratomas.
Lawrenz and colleagues compared the teratoma growth
of J1 ESCs in immunodeficient BALB/c-nude and synge-
neic 129Sv mice [43]. They embedded ESCs in Matrigel
before subcutaneous injection and found that tumor growth
was delayed in syngeneic mice compared to immunodefi-
cient hosts when 2,000 ESCs were injected. In addition,
Table 1 Frequency of teratoma formation after injection of ESCs or in vitro-differentiated cells in various hosts
Host CsA ESC Differentiated cells (day 14)
Syngeneic (129Sv, H2
b) – 96% (25/26) 95% (21/22)
Allogeneic (C57BL/6, H2
b) – 0% (0/19) 0% (0/25)
Allogeneic (C3H, H2
k) – 0% (0/13) 0% (0/21)
Xenogeneic (LOU/c, RT1
u) – 0% (0/12) 0% (0/17)
Allogeneic SCID/beige (C.B-17, H2
d) – 93% (13/14) 94% (17/18)
Allogeneic SCID (C.B-17, H2
d) – 100% (15/15) Not tested
Syngeneic (129Sv, H2
b) + 94% (15/16) 83% (10/12)
Allogeneic (C57BL/6, H2
b) + 0% (0/12) 8% (1/13)
Allogeneic (C3H, H2
k) + 7% (1/15) 9% (1/11)
Xenogeneic (LOU/c, RT1
u) + 0% (0/25) 61% (11/18)
MPI-II ESCs and cells differentiated in vitro for 14 days on PA6 feeder cells (>95% neuronal cells) were injected subcutaneously into the flank of
syngeneicorallogeneicmice orxenogeneic rats (1×10
6 cells/animal). Some recipients received an immunosuppressive treatment with CsA (10 mg/kg/day).
The percentage and number of animals in which tumors were found during autopsy or in which tumors were palpable (at least during three consecutive
observations) at the side of injection before day 100 after injection is indicated. The table is modified from [61]
CsA cyclosprin, ESC embryonic stem cell
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Fig. 1 Teratoma growth after injection of MPI-II ESCs is accelerated
in SCID/beige compared to SCID and syngeneic 129Sv mice. The
1×10
6 MPI-II ESCs were injected subcutaneously at day 0 into
syngeneic 129Sv mice (n=26), T and B cell-deficient SCID (n=14)
and T, B, and NK cell-deficient SCID/beige mice (n=15). The tumor
size was recorded every second day using linear calipers. A summary
of the growth (mean±standard error of the mean) until day 30 is
shown, newly evaluating previously published data [61]. The
comparison of tumor size in SCID and SCID/beige or 129Sv mice,
respectively, indicates a significant difference at days 18, 20, 22, 28,
and 30 (P<0.05, unpaired t test)
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recipients, whereas two ESCs were sufficient to form
teratomas in more than 50% of the immunodeficient
recipients [43].
Some studies determined the cell number required to
form teratomas in syngeneic hosts. It was reported that
5×10
4 or less ESCs did not form teratomas after myocar-
dial transplantation into syngeneic recipients, whereas
1×10
5 cells formed teratomas in 50%, 2.5×10
5 in 80%,
and 5×10
5 in 100% of the mice [60]. In our experiments
aiming to define a tumorigenic dosis of MPI-II ESCs in
syngeneic hosts, 2×10
6 and 1×10
6 MPI-II ESCs formed
teratomas in six out of six syngeneic recipients after subcuta-
neous injection, whereas 5×10
5 cells resulted in teratomas in
two out of six and 1×10
5 in one out of six hosts [61].
Thus,inasyngeneic setting,theimmunesystemappearsto
be able to reject smaller numbers of pluripotent stem cells or
to decelerate teratoma growth after injection of higher
numbers of cells. Notably, it is not clear how regularly
pluripotent stem cells form teratomas after syngeneic trans-
plantation since negative results are unlikely to be reported.
We observed that some pluripotent stem cell lines, which had
readily formed teratomas in immunodeficient hosts, failed to
form teratomas after injection into the syngeneic recipients
(own unpublished observation). However, it is difficult to
exclude the occurrence of genetic alterations between stem
cell generation and transplantation experiments. Mutations
might generate minor histocompatibility antigens that poten-
tially could contribute to the rejection of the stem cell lines in
formally syngeneic hosts.
In conclusion, mouse ESCs can apparently form teratomas
in syngeneic recipients, but the innate immune system might
be able to reject smaller numbers of pluripotent stem cells or
to delay teratoma growth. Only few studies have been
performed to determine the conditions required for teratomas
in syngeneic recipients, such as minimal cell numbers or
favorable injection sites. It is unclear whether newer
pluripotent stem cell types, including iPSCs and maGSCs,
which could potentially be used in autologous cell transplan-
tationprocedures,alsoformteratomasinsyngeneicrecipients.
Although this can be expected, experimental studies are
lacking that would allow to realistically extrapolate the risk of
tumorigenicity associated with autologous pluripotent stem
cell transplantations. In view of the extensively discussed
perspectives of these cells for personalized medicine [83–87],
this is somewhat surprising.
Immune control of teratoma growth—results
from allogeneic transplantations
Some studies have compared syngeneic and allogeneic
transplantations of mouse pluripotent stem cell lines [36,
60, 61, 81, 88–90] or analyzed allogeneic transplantations
only [8, 58, 91–94]. The reported results are remarkably
variable. Obviously, histocompatibility antigens can but
must not suppress teratoma growth after injection of
pluripotent stem cells into allogeneic hosts.
The introduction of genetic markers into ESC lines,
which result in the expression of a single antigen, such as
green fluorescent protein (GFP), usually does not prevent
tumor growth in otherwise syngeneic recipients [60, 88].
However, minor histocompatibility antigens can be suffi-
cient to prevent teratoma growth when ESCs are injected
into hosts that share the major histocompatibility (MHC)
locus but have different genetic backgrounds [60, 61, 65].
The mouse ESC line MPI-II, e.g., which formed teratomas
in syngeneic 129Sv mice (H2
b) after subcutaneous injec-
tion, failed to do so in C57BL/6 mice that share the H2
b
major histocompatibility antigens with 129Sv mice but
have a different genetic background (Table 1)[ 61]. In these
experiments, the injection of male MPI-II cells into female
129Sv recipients had not prevented teratomas [61], indicat-
ing that H-Y minor histocompatibility antigens encoded by
the Y chromosome [95] are not sufficient to suppress
teratomas in this experimental setting. In contrast, teratoma
growth was accelerated in male compared to female hosts,
suggesting an effect of male hormones on teratoma growth.
These ESCs formed also no teratomas in minor and major
histoincompatible C3H/HeN mice (H2
k) (Table 1)[ 61].
Thus, the degree of histocompatibility appears to be one
important factor that determines the outcome of an
allogeneic transplantation. This was also shown in a study
comparing semiallogeneic and fully allogeneic transplanta-
tions [93]. In the semiallogeneic setting, in which 5×10
6
BALB/c x 129Sv-derived ESCs (H2
d and H2
b)w e r e
injected subcutaneously into BALB/c recipients (H2
d),
teratomas grew in 100% of the hosts (n=10) within 21 days.
In the fully allogeneic combination, 1×10
6 C57BL/6-
derived ESCs (H2
b) cells were rejected by BALB/c mice,
but 5×10
6 cells formed teratomas in 30% and 20×10
6 cells
even in 90% of the recipients [93]. Others observed
teratomas after injection of 1×10
6 undifferentiated ESCs
into infarcted hearts in 13 out of 13 syngeneic and two out
of three allogeneic recipients [36].
The rejection of allogeneic mouse ESCs has been
analyzed in more detail. Kofidis and colleagues injected
2.5×10
6 GFP-labeled 129Sv-derived D3 ESCs (H2
b) into
ischemic hearts of immunodeficient SCID, syngeneic
129Sv (H2
b), or allogeneic BALB/c (H2
d) recipients [90].
They followed the grafts up to 4 weeks after transplantation
and found that only a small fraction of grafted cells
developed into cells with a myofibrillar phenotype. The
majority of the graft-derived cells were fibrocytes, chon-
drocytes, adenocytes, and endothelial cells. At 4 weeks,
cellular dysplasia was described, but the grafts were not
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a vigorous graft rejection was observed at 4 weeks with an
infiltration of grafts with CD3
+ T cells, CD11c
+ dendritic
cells, circulation of donor-specific antibodies, and
interferon (IFN)-γ producing ESC-reactive T cells [90]. In
a subsequent study, a higher number (1×10
6) of D3 ESCs
(H2
b) was injected into the ischemic hearts of syngeneic
129Sv (H2
b) and allogeneic BALB/c (H2
d) recipients [81].
After 1 and 2 weeks, the grafts were found in both
recipients without signs of differentiation, indicating sur-
vival of largely undifferentiated ESCs. At 4 weeks,
teratomas had formed in both types of recipients, and at
8 weeks they had been rejected in the allogeneic group in
contrast to syngeneic hosts. Allogeneic ESCs elicited a
progressive graft infiltration with various types of immune
cells, including granulocytes, macrophages, dendritic cells,
and CD4
+ and CD8
+ T cells. The time course of graft
rejection suggested that the immunogenicity of ESC trans-
plants increases with differentiation in vivo. These results
were confirmed by an in vivo imaging study [88]. An
intramuscular injection of 1×10
6 D3 ESCs into syngeneic
129Sv mice resulted in teratomas, whereas grafts in
allogeneic BALB/c mice were infiltrated by CD3
+ and
CD8
+ T cells and rejected within 28 days in all recipients,
unless higher numbers of ESCs were injected. Transplan-
tation of 10×10
6 cells prolonged the survival of the
allografts in some recipients. Interestingly, MHC class I
and class II molecules were found to be strongly upregu-
lated on teratoma cells compared to ESCs. Notably, the
rejection of the 129Sv-derived D3 ESCs was accelerated in
BALB/c mice that were presensitized either with the D3
ESCs or splenocytes of 129Sv mice [88] confirming the
function of the adaptive immune system in the rejection of
allogeneic teratomas.
Similar findings were reported in a further study [60]. In
these experiments, 5×10
5 C57BL/6-derived ESCs (H2
b)
were injected into the myocardium of syngeneic mice and
found to form teratomas. In allogeneic BALB/c recipients
(H2
d), the grafts had proliferated after 1 week. At 2 weeks,
first signs of epithelial differentiation became apparent, and
at 3 weeks teratomas had formed, which were rejected
5 weeks after transplantation in 90% of the mice. The
inflammatory response was compared after syngeneic and
allogeneic transplantations by scoring the number of
infiltrating CD45
+ lymphocytes and found to be increased
markedly at 3 weeks after inoculation of allogeneic
compared to syngeneic stem cells. To test whether the
rejection of allogeneic ESCs was strain or stem cell line
dependent, a second model was evaluated. In this experi-
mental series, 5×10
5 CGR8 ESCs from 129/Ola mice (H2
b)
failed to form tumors in C57BL/6 recipients (H2
b) after
myocardial transplantations [60]. Notably, in this model of
only minor histoincompatibility between transplants and
hosts, the grafts could even not be detected in the
myocardium of the recipients.
The immunological mechanisms involved in the rejec-
tion of allogeneic ESCs were further elucidated by Wu and
colleagues [89]. They injected 1×10
6 cells under the kidney
capsule of immunocompetent mice and found that fully
allogeneic in contrast to syngeneic ESCs were infiltrated by
macrophages, CD4
+, and CD8
+ T cells and rejected within
a few days [89]. However, when ESCs were transfected
with an H2K
b expression construct and transplanted in
immunodeficient RAG1
−/− mice that were adoptively
reconstituted with T cell receptor (TCR)-transgenic BM3
T cells recognizing the MHC class I molecule H2K
b via the
direct pathway of allorecognition, it turned out that the
ESCs or their in vivo differentiation products were not able
to activate a proliferative response of the BM3 T cells. The
BM3 CTLs failed to infiltrate and reject the allografts. This
failure was caused by a lack of professional donor antigen-
presenting cells (APCs) in the graft. Co-transplantation of
mature H2K
b-positive dendritic cells initiated an immune
response of the BM3 CTLs against the allografts. When the
recipients of ESCs were reconstituted with in vitro fully
activated BM3 CTLs by adoptive transfer, the grafts were
readily destroyed within 10 days. Thus, ESC-derived grafts
can be rejected by alloreactive CTLs, if a CTL response
becomes activated.
Not only a lack of donor-derived APCs might impair
alloresponses against ESCs, stem cells might also actively
suppress immune reactions. Yachimovich-Cohen and col-
leagues transplanteda highdoseof15×10
6 C57BL/6-derived
ESCs (H2
b) subcutaneously into BALB/c recipients (H2
d)
[91]. They found teratomas in 39% (7 of 18) of the mice
within 2 to 4 weeks. The teratomas were infiltrated by Tcells
but the CD3 ζ−chain expression levels of these infiltrating T
cells were significantly reduced compared with splenic T
cells from the same mice. This was attributed to the activity
of the immunosuppressive enzyme arginase I in the stem
cells. Arginase I degrades L-arginine and it has been shown
that a low concentration of L-arginine in the microenviron-
ment leads to local T cell unresponsiveness [96].
A very high incidence of teratoma formation after
allogeneic transplantation of mouse ESCs was reported in
a study by Magliocca and colleagues [58]. In an attempt to
induce tolerance for subsequent transplantation of neonatal
cardiac allografts (H2
b), BALB/c mice (H2
d) received an
intraportal injection of 1×10
6 allogeneic ESCs (H2
b)[ 58].
While tolerance to the cardiac allografts was not achieved,
90% of the mice developed intrahepatic teratomas. One
could speculate that the hepatic environment favors
tolerance against the ESCs and therefore tumor formation.
However, the authors reported teratomas also after intrave-
nous or intramuscular injection of the allogeneic ESCs but
gave no details on these experiments [58]. A high risk of
Semin Immunopathol (2011) 33:573–591 579teratomas was observed after transplantation of cynomolgus
monkey ESCs into the fetal liver of allogeneic recipients
[97–99]. In one of these studies, all transplanted animals
developed teratomas although the cell line formed tumors
only in three out of ten NOD/SCID mice [99].
A very low risk of teratomas in allogeneic recipients was
found by Bonde and colleagues. Less than 2% of mice
transplanted intravenously with 1×10
6 or 2×10
6 allogeneic
ESCs developed teratomas but most showed engraftment
leading to multi-lineage mixed chimerism of the hemato-
poietic system of the recipients [94]. Further studies have
reported engraftment of allogeneic cells after transplanta-
tion of undifferentiated ESCs in immunocompetent mouse
models for cardiac repair without tumor formation. Singla
and colleagues transplanted 3×10
4 cells of two different
129-derived ESC lines (H2
b) into the infarcted myocardium
of C57BL/6 mice (H2
b) and found 2 weeks after grafting
differentiation of the transplanted ESCs into cardiac cell
types and improved cardiac function [92, 100]. It has been
debated [36, 60] whether the methods to show engraftment
in these studies were reliable since they based mainly on
GFP or β-galactosidase expression in stem cells and their
derivatives. Autofluorescence can mimic GFP expression
and cell fusion events might occur that lead to expression of
marker genes in hybrid cells. Functional improvement in
these models of myocardial infarction could have been
caused by mechanisms that do not depend on transplant
survival. Thus, either these studies do not reliably indicate a
survival of transplanted cells or they suggest that stem cells
can escape from rejection by differentiation into other cell
types. However, it has also to be noticed that the injected
cell numbers in these studies were low and the observation
time of 2 weeks is likely too short to observe teratomas.
In conclusion, it is well conceivable that the degree of
histocompatibility as well as the circumstances (cell
number, injection site, disease model, etc.) strongly
influence the outcome of the injection of pluripotent stem
cells across histocompatibility barriers. However, the
tremendous variability of tumor risk observed after alloge-
neic stem cell transplantations warrants further studies to
address this question more systematically.
Immune control of teratoma growth—results
from xenogeneic transplantations
Transplantation of mouse and human ESCs into immuno-
competent xenogeneic murine hosts usually does not lead
to teratomas [61, 67, 73, 77] suggesting the rejection of
xenogeneic stem cells or their derivatives formed in vivo by
the recipient’s immune system. However, some studies
have reported engraftment of xenogeneic cells after
transplantation of undifferentiated mouse ESCs in immu-
nocompetent rat models for cardiac repair but there was no
tumor formation [101–103]. Even repeated intravenous
injections of as much as 1×10
7 mouse ESCs did not result
in teratomas in Wistar rats with myocardial infarction but
instead in myocardial homing of ESC-derived cells and
functional improvements [104]. As mentioned before, it not
clear whether methods to show engraftment based on
expression of markers, such as GFP, are reliable. The
short-term functional improvements observed in some
studies after transplantation of xenogeneic ESCs could
have been caused by paracrine effects rather than by
engraftment. However, the complete absence of teratoma
formation suggests that tumorigenic stem cells are dying or
are killed in xenogeneic hosts, even if some cells that
differentiate in vivo might survive.
Effects of immunosuppressive treatment of recipients
In many studies, immunosuppressive drugs, mostly CsA at
doses between 10 and 20 mg/kg/day, were used to avoid the
rejection of pluripotent stem cells transplanted to evaluate
the therapeutic potential of these cells. However, little is
known on the effects of cyclosporine A or other immuno-
suppressive drugs on engraftment, tumorigenicity, or
differentiation of transplanted pluripotent stem cells.
In one study, the therapeutic effect of very low doses of
undifferentiated mouse ESCs was evaluated in a rat model
of Parkinson’s disease [105]. As few as 2×10
3 to 4×10
3 D3
ESCs were transplanted into the striatum of 6-
hydroxydopamine (OHDA)-lesioned rats resulting in
teratomas in 5 out of 25 recipients. In other animals, the
ESCs developed into dopaminergic neurons and a functional
improvement of disease symptoms was reported. These rats
received an immunosuppressive treatment with 15 mg/kg/day
CsA. In a similar approach in a neurotrauma model, Sprague–
Dawley rats were injected with 1×10
5 D3 mouse ESCs and
two of ten animals developed tumors [106]. One of these
was characterized as a chondroma. These animals received
10 mg/kg/day CsA. The transplantation of the same ESCs
into intact rat brains resulted in teratomas or teratocarcino-
mas in five out of eight animals within 2 weeks [107],
suggesting that the inflammatory response to tissue damage
in a disease model can alleviate the rejection of tumorigenic
cells. Interestingly, the transplantation of 5×10
6 D3 ESCs
into the infarcted hearts of Sprague–Dawley rats resulted in
teratomas in 80% of the recipients, which were immunosup-
pressed with CsA (10 mg/kg/day) and methylprednisolone
(2 mg/kg/day) [108]. It would be worthwhile to investigate
whether an additional anti-inflammatory therapy could
increase the tumor risk. Human ESCs can also result in
tumors when transplanted into the brain of CsA-treated
6-OHDA-lesioned rats [45]. Injection of 5×10
5 H1 or H9
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20 mg/kg/day) Sprague–Dawley rats resulted in highly
undifferentiated tumor masses within 4 weeks. Similarly,
the injection of 3×10
6 or 1.5×10
6 human ESCs into
healthy or infarcted hearts of CsA-treated rats (15 mg/kg/day)
resulted in teratoma-like structures [109].
Low numbers of mouse ESCs (4×10
2 to 4×10
3) were
reported to generate neurons after transplantation into the
brain of CsA-treated allogeneic recipients without teratoma
formation, at least within 14 days [110]. Presumably,
allogeneic mouse iPSCs (5×10
5) formed teratomas prefer-
entially in ischemic compared to sham-operated brains of
C57BL/6 mice treated with CsA (10 mg/kg/day) [111].
Notably, 0.5×10
6 to 1×10
6 maGSCs injected into the
normal heart of partially allogeneic C57BL/6 mice (treated
with 10 mg/kg CsA per day) were found to proliferate and
to differentiate but not to form tumors within 1 month after
transplantation [8]. Erdö and colleagues transplanted
129Sv-derived D3 ESCs (H2
b) into the striatum of 129Sv
(H2
b) or C57BL/6 (H2
b) recipients, in some of which a
focal brain ischemia had been elicited [27]. The numbers of
transplanted cells varied between 500 and 5×10
4 but
tumors developed at high frequency in all experimental
groups (75% to 100% of the recipients). The tumors were
characterized as highly malignant and invasive teratocarci-
nomas. The tumorigenesis was independent of the location
of implantation, presence or absence of immunosuppres-
sion, gender, age, and strain of the mice but these results
were not shown in detail [27]. Notably, tumor risk in
xenogeneic recipients, i.e., Wistar rats, was very low. Only
2 of 32 rats developed small tumors near the place of
implantation [27]. Interestingly, the xenotransplantation to
the hemisphere opposite to the ischemic brain injury
resulted in migration towards the lesion and differentiation
into neuronal cells in the boarder zone of the lesion [27].
Thus, in the setting of a xenotransplantation combined with
immunosuppression by CsA, the immune system might still
contribute to the eradication of tumorigenic cells but allow a
therapeutic effect of in vivo differentiated non-tumorigenic
cells.
In an approach of comparing various immunogenetic
settings, we evaluated teratoma growth in CsA-treated hosts
and untreated controls [61]. After subcutaneous injection of
1×10
6 MPI-II ESCs (H2
b) into syngeneic (129Sv H2
b),
allogeneic (C57BL/6, H2
b and C3H/HeN, H2
k)a n d
xenogeneic (LOU/c rats, RT1
u) recipients, the frequency
of teratomas was mainly unaffected by CsA at a dose of
10 mg/kg/day (Table 1). Only the syngeneic recipients
developed teratomas with exception of 1 out of 15 CsA-
treated allogeneic C3H/HeN recipients, in which a very
small tumor was observed [61].
Swijnenburg and colleagues compared the effects of
different classes of immunosuppressive drugs represented
by tacrolimus, sirolimus, and mofetil on the survival of
human ESCs after intramuscular injection into BALB/c
mice [77]. The transplanted cells were rejected within
10 days in all single drug treatment groups and only a
combination of tacrolimus and sirolimus extended cell
survival to day 28 [77]. Interestingly, it was shown in
another study that human ESCs form teratomas in the testis
(not in the heart) of C57BL/6 mice just after transient
blockade of co-stimulatory signals (CD40L, CTLA-4, and
LFA-1) [73].
In conclusion, immunosuppressive treatment might
increase the risk of teratoma formation after pluripotent
stem cell transplantation at least in some experimental
models. However, systematic studies evaluating the
effects of immunosuppressive treatment and comparing
the currently available immunosuppressive drugs in the
context of pluripotent stem cell transplantation are
largely lacking.
Tumor risk after transplantation
of in vitro-differentiated cells
In many studies, pluripotent stem cells were differentiated
before transplantation in order to avoid tumor formation.
Some used immunodeficient mouse models to determine
the tumor risk of pre-differentiated cells. Hentze and
colleagues compared the teratoma growth of undifferenti-
ated human ESCs with in vitro-differentiated cardiomyo-
cytes and beta cells after intramuscular injection into SCID
mice and found that the growth kinetics of teratomas were
similar [44]. Others studies investigated differentiated cell
populations only and reported a high risk of teratoma
formation [112, 113]. A purity of 99.8% insulin-positive
cells derived from mouse ESCs was not sufficient to
prevent teratoma growth in NOD/SCID mice that were
transplanted to treat diabetes [112]. Recently, neuronal cells
differentiated in vitro from a large number of iPSC clones
were transplanted into the brain of NOD/SCID mice. It
turned out that the teratoma risk substantially varied
dependent on the tissue that was used to generate the
iPSCs [114]. This might reflect the genetic variation of
iPSC lines [29–31].
Interestingly, ESC-derived haematopoietic cells could be
rejected in Rag2
−/− hosts, while the cells could engraft
Rag2
−/−cγc
−/− mice, in which in addition to T and B cells
also NK cells are deleted [115, 116]. Similarly, the
engraftment of NOD/SCID mice with human ESC-derived
haematopoietic cells was improved by antibody-mediated
NK cell depletion [71]. The transplantations of ESC-
derived vascular progenitors indicated that NK cells can
also play a role in the rejection of these progenitor cells in
syngeneic recipients [117]. In all these studies, no teratomas
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progenitor cells can be rejected by elements of the innate
immune system, such as NK cells. Moreover, also human
neural progenitor cells were demonstrated to be efficiently
killed by NK cells [118], suggesting that this problem is
also relevant for human ESC-derived progenitor cells.
Robertson and colleagues transplanted embryoid body
(EB)-derived cells under the kidney capsule of various
recipients [65]. Syngeneic transplantations resulted in
teratomas, whereas fully allogeneic cells were eventually
rejected similarly to EBs with a single foreign MHC
class I locus and EBs that differed only in minor
histocompatibility antigens. The rejection was associated
with a substantial inflammatory response. In a subse-
quent study, male ESC-derived EBs (CBK, H2
k)w i t ha
single MHC mismatch (K
b) were shown to be accepted in
50% of male hosts (CBK, H2
k) for 28 days, but rejected in
all female recipients at that time point, suggesting a role of
H-Y antigens in the rejection of EBs [119].
Also, other studies reported a high risk of teratoma
formation after transplantation of ESC-derived differentiated
cell populations into syngeneic hosts. Transplantation of
6×10
4 differentiated cells (90% positive for the neuronal
marker nestin) into the subretinal space resulted in teratomas
in 50% of the syngeneic recipients within 2 months after
transplantation [80]. However, the tumor risk appears to
depend on the purity of the differentiated cell population.
Highly purified cardiomyocytes (>99% pure) transplanted
into the myocardium of syngeneic mice formed no
teratomas. However, in 3 out of 60 recipients malignant
fibrous histiocytomas were found [36].
V e r yi n t e r e s t i n gr e s u l t sw e r eo b t a i n e db yW ua n d
colleagues [89]. They transplanted ESC-derived insulin-
producing cell clusters into diabetic immunodeficient
RAG1
−/− mice and achieved normoglycemia for several
days. The grafts failed to activate adoptively transferred
alloreactive TCR-transgenic BM3 CTLs likely due to the
absence of donor APCs in the grafts. Nonetheless, the
grafts were rapidly rejected in allogeneic and even
syngeneic immunocompetent recipients. Thus, the
ESC-derived grafts might express novel immunogenic
antigens that are not present in the adult organism so
that no tolerance has been established. The effects of
NK cells have also to be taken into consideration in
this model.
Further reports on the outcome of allogeneic trans-
plantations of in vitro-differentiated cells indicate a high
variability. Even early differentiated cells were reported to
engraft without forming teratomas in a model of myocardial
infarction [120]. Again, the possibility should not be
dismissed that tumorigenic cells might be killed more
efficiently in an inflamed tissue compared to models
evaluating transplantations into intact organs. It has been
concluded from a murine model of myocarditis, in which
no tumors were observed, that inflammation might have
further beneficial effects on homing, differentiation, and
integration of intravenously administered allogeneic ESCs
[121]. Endodermal precursor cells differentiated from ESCs
of 129Sv mice (H2
b) were evaluated for their ability to
correct a factor IX deficiency in C57BL/6 mice (H2
b) and
fully allogeneic BALB/c mice (H2
d). In minor histoincom-
patible C57BL/6 recipients, 6 out of 64 mice (9%)
developed teratomas and in minor plus major histoincom-
patible BALB/c mice 1 out of 18 (6 %) [122]. Swijnenburg
and colleagues reported that pre-differentiated mouse ESCs
were more rapidly rejected in allogeneic hosts than
undifferentiated ESCs [88].
In vitro pre-differentiation of mouse and human ESCs
has been successful in several xenograft models, in
which no tumors were observed after transplantation into
CsA-treated recipients [45, 109, 123–128] or into nude
rats [129]. However, teratoma formation was reported in
some studies to depend on the duration of in vitro
differentiation of the transplanted cells [33]o ro nt h e
immunosuppressive treatment of the recipients [130].
Others have even indicated graft rejection without thera-
peutic effects: Transplantation of cardiac-committed
mouse ESCs into infarcted baboon hearts, e.g., resulted
in graft rejection likely mediated by T lymphocytes and
NK cells [131].
Notably, ESC-derived xenografts transplanted into an
immune-privileged organ, such as the brain, can survive
without immunosuppression. This was shown by Baier and
colleagues [132] who transplanted dopaminergic neurons,
differentiated in vitro for 14 days on PA6 feeder cells, into
the striatum of unilaterally 6-OHDA-lesioned rats. The
grafted cells survived in the absence of immunosuppression
for at least 5 weeks after transplantation, although they
showed no signs of morphological integration into the host
tissue. Nonetheless, the transplantation improved the
rotational behavior of the rats, serving as model of
Parkinson’s disease [132]. When the recipients were treated
with CsA, the morphological integration appeared to be
improved, but now 2 of 15 recipients developed teratomas
[130]. Although the reduction of tumor risk is one of the
major aims of in vitro differentiation of stem cell grafts, a
systematic comparison of teratoma formation after trans-
plantation of undifferentiated and differentiated cells has
rarely been performed.
The results reported by Baier [132] and Thinyane
[130] prompted us to analyze the tumorigenicity of
undifferentiated ESCs and in vitro-differentiated neuronal
cells in more detail [61]. Similar numbers (1×10
6)o f
undifferentiated MPI-II ESCs (H2
b) and neuronal cells
differentiated in vitro were subcutaneously injected into
immunodeficient SCID/beige, syngeneic (129Sv H2
b),
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b, and C3H/HeN, H2
k)
and xenogeneic (LOU/c rats, RT1
u) recipients. The
immunocompetent animals were either treated with CsA
(10 mg/kg/day) or not (Table 1). About 95% of the cells
from the differentiation cultures were positive for the
neuronal marker Tuj1 and 30% of the neurons were
positive for tyrosine hydroxylase indicating a dopaminer-
gic differentiation [61, 132]. Less than 5% of the colonies
in the differentiation cultures contained OCT3/4 and Ki67-
positive cells, which might represent still undifferentiated
ESCs [61]. Teratomas were detected in immunodeficient
and syngeneic recipients after injection of undifferentiated
as well as differentiated cells at a similar high frequency of
about 95% and with similar growth kinetics in contrast to
allogeneic or xenogeneic recipients (Table 1). Such a
finding is usually attributed to the contamination of in
vitro-differentiated cell populations with still undifferenti-
ated ESCs [40], although it was under this assumption
surprising that teratoma growth was not markedly decel-
erated in mice injected with the differentiated cell
population. However, this view was challenged by the
results obtained in CsA-treated recipients (Table 1).
Syngeneic recipients still developed teratomas and in
allogeneic mice very small tumors were observed in single
cases. The surprising finding was a high incidence (61%)
of rapidly growing teratomas in CsA-treated rats after
injection of differentiated cells (containing clearly less
than 5% ESCs) in contrast to pure undifferentiated ESCs
[61]( T a b l e1). This finding indicates the existence of a
cell type in the differentiation cultures different from ESCs
that is still pluripotent and can give rise to teratomas. This
cell population is apparently not tumorigeneic in immu-
nocompetent rats because animals that were not treated
with CsA did not develop teratomas. Importantly, the
undifferentiated ESCs were not tumorigenic even in CsA-
treated recipients. Thus, the immune control of this
putative pluripotent cell type present in differentiation
cultures might depend on T cells that were inhibited by
CsA. The undifferentiated ESCs, in contrast, can appar-
ently be controlled sufficiently by immune mechanisms
that are not inhibited by CsA. We found evidence for a
high activity of NK cells in rats that kill the undifferen-
tiated ESCs but not the in vitro-differentiated cells [61].
These data suggest that a cell type can occur in
differentiation cultures, which already lost susceptibility
to innate immune mechanism, such as NK cells, but still is
pluripotent and tumorigenic (Fig. 2). It remains to be
elucidated whether only the ESC line and differentiation
procedure evaluated in our study [61] generates those cells
or whether this is a more general phenomenon. Interest-
ingly, Preynat-Seauve and colleagues recently reported
that the NK cell-mediated killing of human ESC-derived
neural progenitor cells was not inhibited by CsA in
contrast to further differentiation of progenitors into
neurons [118]. Thus, an escape from NK cell killing by
differentiation into NK cell resistant neurons might be
inhibited by CsA.
In conclusion, the immune system of recipients appears
to contribute to the control of tumorigenicity of stem cell-
derived transplants. Apparently, not only completely undif-
ferentiated stem cells can give rise to teratomas and various
tumorigenic cell types appear to be rejected preferentially
by different immune mechanisms.
Immune effector mechanisms contributing
to the rejection of pluripotent stem cell-derived
teratomas
Several immune effector mechanisms appear to be impor-
tant for the rejection of pluripotent stem cell-derived
teratomas, including T cells [67], NK cells [61, 71, 75],
and the complement system [59]. Different effector mech-
anisms might be important for the recognition and
elimination of pluripotent stem cells and cells that differ-
entiate from stem cells either in vitro before or in vivo after
transplantation. The cells differentiated in vitro from ESCs
were found to be less susceptible to killing by NK cells [61,
133] and the alternative complement pathway [59] than
undifferentiated ESCs. Other experiments suggest that
recognition by T cells increases with differentiation [60,
81, 90] suggesting a negative effect of the adaptive immune
system on engraftment of differentiated cells. The efficacy
of these various effector mechanisms in suppression of
tumors and graft rejection presumably differs dependent on
the immunogenetic setting of transplantations, whether it is,
e.g., a syngeneic, allogeneic, or xenogeneic transplantation.
Some of these effector mechanisms are profoundly sup-
pressed by immunosuppressive treatment with drugs, such
as CsA, but others are not.
Several studies suggest that CTLs play a major role in
the rejection of teratomas derived from pluripotent stem
cells [88, 89, 93, 119]. The recognition structures for CTLs
on target cells, the polymorphic MHC class I molecules, are
assumed to represent the most important immunological
barrier for transplantation of pluripotent stem cell-derived
allografts [134, 135]. The MHC class I molecules are
targets for alloreactive CTLs either by direct or indirect
allorecognition [134, 135] but minor histocompatibility
antigens, which are presented by MHC class I molecules,
have also been shown to contribute to the rejection of ESC-
derived grafts by CTLs [61, 65, 119]. However, in a
xenotransplantation of human ESCs into murine hosts
direct allorecognition by CTLs might be less relevant due
to a lower affinity of mouse TCRs to human MHC class I
molecules. Instead indirect allorecognition by CD4
+ helper
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of human ESCs by mouse recipients [77].
Notably, MHC class I molecules are not detectable by
flow cytometry on mouse ESCs [11, 58, 60, 61, 75, 89, 94,
133, 136, 137] and other pluripotent mouse stem cell types
including maGSCs and iPSCs [11, 75]. Despite being
negative for MHC class I molecules, we analyzed a number
of pluripotent mouse stem cell lines, including two ESC
lines, two maGSC lines, and one iPSC line, for suscepti-
bility to killing by CTLs. All tested stem cell lines were
readily killed in a peptide-dependent manner by activated
CTLs derived from TCR-transgenic OT-I mice that recog-
nize the peptide SIINFEKL in the context of H2K
b
molecules, although less efficiently than RMA lymphoma
cell used as positive control [11]. This finding is in
accordance with studies showing that extremely low
numbers of MHC molecules on target cells are sufficient
for CTL recognition and killing [138–140]. In contrast to
our findings, Abdullah and colleagues reported that the
recognition of CGR8 ESCs by CTLs is not sufficient for
killing due to the expression of serpin SPI-6 [137, 141],
which is an endogenous inhibitor of granzyme B [142].
However, all pluripotent stem cell lines that we analyzed
were uniformly negative for SPI-6 and susceptible to CTL
killing mediated in the granule exocytosis pathway [11, 75].
Activated alloreactive CTLs were reported to modestly kill
IFN-γ treated [94] but not untreated RW-4 ESCs [143].
Thus, pluripotent stem cell lines are not generally immune-
privileged due to low expression of MHC class I molecules
and resistance to CTL-mediated killing, although different
cell lines might vary considerably. It remains to be analyzed
whether pluripotent stem cells can process endogenous
antigens for presentation on MHC class I molecules. If so,
peptides derived from proteins that are exclusively
expressed in pluripotent stem cells, such as OCT3/4 or
NANOG, might function as tumor antigens.
Importantly, the expression of MHC class I molecules
has been reported to increase during in vitro [144]o ri n
vivo differentiation of mouse ESCs [65, 88–90, 93].
Furthermore, MHC class I molecules are inducible by
IFN-γ in mouse ESCs [89, 94] and human ESCs [145]o ri n
differentiated cells [118, 133, 137] and IFN-γ and other
pro-inflammatory cytokines are present in at least some
transplantation models associated with inflammation [90,
119]. Thus, ESCs and their differentiation products might
become even better targets for CTLs after transplantation of
differentiated cells or in vivo differentiation [60, 65, 81,
89]. Human ESCs, in contrast to mouse ESCs, were shown
to express low but in flow cytometry detectable levels of
MHC class I molecules [144–146] and reported to be
susceptible to killing by human CTLs [76]. Human ESC-
derived neural progenitor cells were able to induce
allogeneic T cell proliferation especially after treatment
with IFN-γ, which induces expression of MHC class I
molecules [118].
MHC class I molecules are not only antigen-presenting
molecules and recognition structures for CTLs. They
function also as ligands for inhibitory NK receptors and
prevent the killing of uninfected and non-malignant cells by
NK cells [147]. The “missing self” concept implies that
cells lacking MHC class I molecules due to virus infection
or malignant transformation become targets for NK cells
[148]. Thus, it was surprising that ESCs were reported to be
resistant to NK cells [93, 94] or only very moderately killed
by activated NK cells [94]. We found that unstimulated rat
NK cells readily killed mouse ESCs and that IL-2-activated
syngeneic and allogeneic mouse NK cells also killed ESC
targets [61, 75]. This appears to be a regular phenotype of
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Fig. 2 Schematic representation
of factors which influence the
outcome of pluripotent stem cell
transplantations. Besides graft-
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host-related factors in first line
immune-mediated rejection
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the outcome of transplantations
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584 Semin Immunopathol (2011) 33:573–591pluripotent stem cells because all pluripotent mouse stem
cell lines that we investigated, including four ESC lines,
four maGSC lines, and one iPSC line, were highly
susceptible targets for activated NK cells derived from
syngeneic, allogeneic, and xenogeneic donors; some of
them were even better killed than the conventional NK
target cell line YAC-1 [75]. In accordance with these data,
four other ESC lines were also reported to be killed by
activated mouse NK cells although less efficiently than
YAC-1 cells [133].
The cytotoxic activity of NK cells is not only controlled
by inhibitory receptors recognizing MHC class I molecules
but also by a diverse set of activating receptors that
recognize specific ligands on targets. Most mouse plurip-
otent stem cell lines appear to express some ligands for
activating NK receptors and most frequently ligands for the
activating receptor NKG2D [61, 75, 133]. The recognition
of these ligands by NK cells is known to trigger
cytotoxicity [149]. Normally, NKG2D ligands are not
expressed on healthy cells but they can become induced
by conditions, such as heat shock [150], virus infection
[151], or genotoxic stress [152]. The NKG2D ligands
appear to signal the presence of potentially dangerous cells
to the immune system [153] and they contribute to tumor
immune surveillance [149]. NKG2D ligands are a hetero-
geneous group of molecules consisting in the mouse of the
RAE-1 family, MULT-1, and H60 proteins [149]. The
NKG2D ligands found to be expressed on pluripotent stem
cell lines belong to the RAE-1 family only [61, 75].
Interestingly, the RAE-1 molecules were initially cloned
from pluripotent F9 teratocarcinoma cells [154] that are
also highly susceptible to killing by NK cells [75, 155,
156]. The functional relevance of NKG2D ligands could be
demonstrated by inhibition of NK cell-mediated stem cell
killing by soluble NKG2D molecules [61, 75]. RW-4
mouse ESCs have also been reported to express RAE-1
molecules but to trigger only a modest cytotoxicity of
activated NK cells [94]. However, since it was reported that
ICAM-1 expression on ESCs is critical for NK cell-
mediated killing [133], the presence of RAE-1 molecules
must not be sufficient to trigger lysis. In addition to
NKG2D ligands, many pluripotent stem cell lines express
CD112 and CD155 [75], the ligands of the activating NK
receptor DNAM-1 (CD226) [157]. These ligands were also
reported recently to be important for the killing of stem
cell-like glioblastoma cells by NK cells [158]. In our set of
pluripotent mouse stem cell lines, we found no ligands of
the NK receptors 2B4 and NKp46 to be expressed. The lack
of NKp46 ligands on ESCs is in accord with another report
[133]. Human ESCs have been shown to express small
amounts of ligands for the activating NK receptor NKp44
and to be killed moderately by human NK cells [146].
Human ESCs were recently shown also to express low
levels of MICA and MICB human ligands for NKG2D
[159]. Human ESC-derived neural progenitors cells have
been reported also to express MICA and MICB as well as
the NKG2D ligands ULBP-1, 2, and 3 [118]. These cells
were killed by IL-15-stimulated NK cells in an NKG2D-
dependent manner [118]. Thus, a set of ligands for
activating NK receptors, in addition to absence of ligands
of inhibitory NK receptors, can determine the susceptibility
of pluripotent stem cell lines to NK cells and every cell line
appears to have a specific expression pattern of such
ligands [75]. Moreover, it has been shown that the
transplantation of ESCs can give rise to antibodies that
bind to cell surface molecules on ESCs [90]. Therefore,
antibody-dependent cellular cytotoxicity, mediated by NK
cells or other effectors, could likely also contribute to the
rejection of stem cell grafts.
Notably, in vitro differentiation of stem cell lines
increases resistance to NK cells [61, 75, 133]. The
resistance of differentiated neuronal cells [61], cardiomyo-
cytes [133], or mixed cell populations [75] correlated with
the downregulation of NKG2D ligands on these cells much
better than with increased expression of MHC class I
molecules that serve as ligands for inhibitory NK receptors.
However, in one study, an upregulation of the NKG2D
ligand H60 on ESCs-derived hematopoietic progenitors was
observed resulting in lysis of these progenitors by NK cells
[116]. Notably, the differentiated cells, in contrast to ESCs,
were also reported to be resistant to the alternative
antibody-independent complement pathway [59].
In conclusion, all immune effector mechanisms, which
have been explored in some detail, can apparently
contribute to the rejection of pluripotent stem cells or stem
cell-derived grafts under certain conditions. This includes
effector functions of the adaptive and innate immune
system. Transplanted cells types, such as undifferentiated
pluripotent stem cells, precursor cell populations, or various
terminally differentiated cell types can differ in their
susceptibility to these immune effector mechanisms. Nota-
bly, variations might be exploitable to suppress tumorigenic
cells while allowing for engraftment of therapeutically
active cells.
Immune-privileged and immunosuppressive versus
immunogenic properties of pluripotent stem cells
and pluripotent stem cell-derived grafts
Several studies have suggested that mouse or human ESCs
have immune-privileged [67, 93, 94, 137, 146], immuno-
suppressive [91, 93, 94, 119, 145], or tolerance-inducing
[143] properties. They may suppress immune responses by
contact dependent and contact independent mechanisms,
including production of immunosuppressive cytokines,
Semin Immunopathol (2011) 33:573–591 585such as transforming growth factor (TGF)-β [65, 93] and
interleukin (IL)-10 [119], depletion of amino acids, such as
L-agrinine that are required for T cell activation [91], or
induction of apoptosis in alloreactive T cells via FasL on
ESCs [94, 143]. It has been suggested that tolerance might
be more easily achievable for ESC-derived grafts because
TGF-β favors the polarization of infiltrating T cells toward
a regulatory phenotype [65, 119]. However, in another
study, tolerance against subsequent allografts was not
achieved by ESC transplantation [93].
Meanwhile, it has become clear from several studies that
allogeneic pluripotent stem cells are frequently rejected [60,
81, 90], although their destruction might be delayed because
the immunogenicity of transplanted cells increases upon
differentiation in vivo [60, 81] or immunosuppressive effects
of ESCs are transiently effective [65, 91, 119]. Notably, the
transplantation of pluripotent stem cells can induce an
immunological memory. The rejection of the 129Sv-
derived D3 ESCs was accelerated in BALB/c mice that
were presensitized with the ESCs [88]. Similarly, ESCs were
shown to sensitize the recipients leading to an accelerated
rejection of a subsequent skin allograft. Interestingly, this
was observed only in animals that rejected the ESCs and not
in animals in which teratomas were formed [93].
Nonetheless, pluripotent stem cell-derived grafts are
presumably less immunogenic than conventional allografts
due to low expression of MHC class I molecules, lack of
professional APCs, failure to stimulate a direct allores-
ponse, and further more specific mechanisms. However,
this low immunogenicity appears to be fragile and can
rather easily be overcome [89]. Importantly, numerous
studies have shown that pluripotent stem cell or their
derivatives are at risk to form tumors after syngeneic,
allogeneic, and even xenogeneic transplantations. It will be
worthwhile to further determine to which extent the
immunosuppressive mechanisms of pluripotent stem cells
contribute to this unwanted outcome.
Conclusions
Pluripotent stem cells clearly hold great promises for
the replacement of diseased cells and tissues by
transplantation of stem cells or, more likely, their in
vitro-generated derivatives. However, pluripotency and
tumorigenicity are closely related features of stem cells.
Therefore, the risk of tumor formation must be resolved
before clinical application of any kind of pluripotent
stem cell therapy. Numerous studies have shown that
pluripotent stem cells can form teratomas and other
tumors in immunodeficient, syngeneic, allogeneic, and
even xenogeneic recipients, depending on the condi-
tions of transplantation. However, the immune system
of the recipient does not only has profound effects on
engraftment of stem cell-derived transplants but also on
tumor formation (Fig. 2). The innate immune system,
e.g., NK cells and complement system, appears to be able
to reject smaller numbers of pluripotent stem cells even in
some immunodeficient and, importantly, in immunocom-
petent syngeneic recipients. The innate and adaptive
immune mechanisms apparently can also impair engraft-
ment of syngeneic stem cell transplants. This should be
noted for future autologous pluripotent stem cell thera-
p i e s ,m a k i n gu s eo fi P S C s ,w h i c hs o o nm i g h tb e c o m e
available for regenerative medicine. Notably, this might
be even of advantage, if the immune system of immuno-
competent recipients can be exploited to preferentially
kill tumorigenic cells, which contaminate grafts in trace
amounts despite all efforts to reduce their numbers before
transplantation. Since pluripotent stem cells might not be
used solely in autologous settings, it will be important to
carefully analyze alloimmune responses against tumori-
genic as well therapeutically beneficial stem cell deriva-
tives in models representing the various possible
immungenetic scenarios. Variations in the immune re-
sponse against undifferentiated pluripotent stem cells,
precursor cell populations, or terminally differentiated
cell types in immunocompetent or immunosuppressed
recipients can apparently determine the outcome of
experimental transplantations with respect to engraftment
and tumor development. This has to be taken into account
to correctly interpret the results of therapy models and for
future translation into clinical practice.
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